An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

Completed · Phase 2

Conditions studied: Neovascular Age-related Macular Degeneration

In brief

This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PrONTO) study.

Key facts

Study ID: NCT00373659
Run by: University of Miami
People needed: 40
Starts: 2004-08-01
Expected to finish: 2007-06-01
Last updated by the study team: 2012-06-13

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 50 years or older
Active primary or recurrent macular neovascularization secondary to age-related macular degeneration (AMD) involving the central fovea in the study eye with evidence of disease progression
OCT central retinal thickness ≥ 300 microns
Best corrected visual acuity, using ETDRS charts, of 20/40 to 20/400 (Snellen equivalent) in the study eye

You may not qualify if…

More than 3 prior treatments with verteporfin photodynamic therapy
Previous participation in a clinical trial (for either eye) involving antiangiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors)
Previous subfoveal focal laser photocoagulation in the study eye
Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding day 0
Subfoveal fibrosis or atrophy in the study eye
History of vitrectomy surgery in the study eye
Aphakia or absence of the posterior capsule in the study eye
History of idiopathic or autoimmune-associated uveitis in either eye

Where it is running

Bascom Palmer Eye Instiyute — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.